We have previously shown that blocking of CPT1 by an irreversible CPT1 antagonist or by genetic inhibition show clinical-relevant effects in in vivo models of neurodegenerative diseases, diminishes inflammation, demyelination oxidative stress and increases mitochondrial biogenesis20,22–24. Here, CPT1A is linked to neurodegenerative disease.